Wall Street's major averages ended lower on Friday, with the S&P 500 (SP500) and the Nasdaq (COMP:IND) ending the week in the ...
For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Welcome The Hill’s annual list of Top Lobbyists. President Trump’s return to the White House brought a whirlwind of policy ...
Eli Lilly plans API plant in Alabama to produce small molecule and peptide medicines, creating 450 jobs and enhancing U.S. pharmaceutical supply chains.
Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply ...
French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...
Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create ...
Eli Lilly plans to start work next year on a facility that will produce orforglipron, officials announced Tuesday in Huntsville.
Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...
Health-care companies fell as traders weighed risks in a wave of deal activity. Pfizer joined Big Pharma rivals hunting for novel weight loss drugs in the Chinese biotech sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback